Clinical Trial Update: A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MOXR0916 with atezolizumab versus atezolizumab alone in untreated locally advanced or metastatic urothelial carcinoma ineligible for ci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• MOXR0916 (MOXR0916)

Snippet

Sponsor: Genentech, Inc. | Conditions: Urothelial Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-05-31